Cara Therapeutics Inc (NASDAQ:CARA) Stock Position Lifted by Mesirow Financial Investment …

Two Sigma Investments LP purchased a new stake in shares of Cara Therapeutics during the fourth quarter worth $1,578,000. BlackRock Inc. grew its …

Cara Therapeutics logoMesirow Financial Investment Management Inc. increased its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 12.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,432 shares of the biopharmaceutical company’s stock after purchasing an additional 3,611 shares during the period. Cara Therapeutics accounts for about 2.6% of Mesirow Financial Investment Management Inc.’s portfolio, making the stock its 3rd largest position. Mesirow Financial Investment Management Inc. owned about 0.08% of Cara Therapeutics worth $719,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in CARA. Deutsche Bank AG increased its holdings in Cara Therapeutics by 141.9% in the 4th quarter. Deutsche Bank AG now owns 304,177 shares of the biopharmaceutical company’s stock worth $3,953,000 after acquiring an additional 178,414 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Cara Therapeutics by 17.3% during the first quarter. First Manhattan Co. now owns 981,220 shares of the biopharmaceutical company’s stock worth $19,251,000 after buying an additional 144,578 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cara Therapeutics during the fourth quarter worth $1,578,000. BlackRock Inc. grew its holdings in shares of Cara Therapeutics by 1.5% during the fourth quarter. BlackRock Inc. now owns 2,800,605 shares of the biopharmaceutical company’s stock worth $36,407,000 after buying an additional 42,487 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Cara Therapeutics by 109.5% in the fourth quarter. Two Sigma Advisers LP now owns 39,600 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 20,700 shares during the period. Institutional investors and hedge funds own 58.03% of the company’s stock.

In related news, CEO Derek T. Chalmers sold 5,528 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $21.42, for a total transaction of $118,409.76. Following the transaction, the chief executive officer now directly owns 963,996 shares of the company’s stock, valued at approximately $20,648,794.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frederique Ph.D. Menzaghi sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $23.24, for a total value of $464,800.00. Following the completion of the sale, the senior vice president now owns 99,886 shares of the company’s stock, valued at $2,321,350.64. The disclosure for this sale can be found here. Insiders have sold a total of 120,848 shares of company stock valued at $2,844,442 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Shares of NASDAQ CARA opened at $23.99 on Friday. Cara Therapeutics Inc has a 1-year low of $12.19 and a 1-year high of $27.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.11 and a quick ratio of 3.11. The stock has a fifty day moving average price of $23.59 and a 200 day moving average price of $19.96. The company has a market cap of $953.65 million, a PE ratio of -11.65 and a beta of 2.18.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.03. The company had revenue of $5.21 million during the quarter, compared to the consensus estimate of $5.14 million. Cara Therapeutics had a negative return on equity of 68.36% and a negative net margin of 420.97%. Analysts anticipate that Cara Therapeutics Inc will post -2.32 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the stock. Piper Jaffray Companies upped their price objective on shares of Cara Therapeutics from $35.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 12th. Laidlaw upped their price objective on shares of Cara Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, May 29th. Needham & Company LLC upped their target price on shares of Cara Therapeutics from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, May 29th. Finally, BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Cara Therapeutics has an average rating of “Buy” and an average price target of $26.94.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

See Also: What is Compound Interest?

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Cara Therapeutics (NASDAQ:CARA) Stock Price Down 13.4%

Two Sigma Investments LP purchased a new stake in shares of Cara Therapeutics during the 4th quarter valued at $1,578,000. BlackRock Inc. lifted …

Cara Therapeutics logoCara Therapeutics Inc (NASDAQ:CARA)’s stock price traded down 13.4% during mid-day trading on Thursday . The stock traded as low as $22.74 and last traded at $22.75, 4,452,860 shares changed hands during mid-day trading. An increase of 489% from the average session volume of 755,518 shares. The stock had previously closed at $26.27.

Several research analysts recently issued reports on the company. Needham & Company LLC increased their price objective on Cara Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, May 29th. BidaskClub cut YY from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Zacks Investment Research raised DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. HC Wainwright increased their price objective on Cara Therapeutics from $28.00 to $31.00 and gave the stock an “average” rating in a research note on Monday. Finally, Laidlaw increased their price objective on Cara Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, May 29th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Cara Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.58.

The stock has a fifty day simple moving average of $22.01. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.40 and a quick ratio of 3.40.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). The company had revenue of $4.38 million for the quarter, compared to analysts’ expectations of $5.14 million. Cara Therapeutics had a negative return on equity of 67.30% and a negative net margin of 443.71%. On average, analysts forecast that Cara Therapeutics Inc will post -2.38 earnings per share for the current fiscal year.

In other news, Director Jeffrey L. Ives sold 2,500 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $21.75, for a total transaction of $54,375.00. Following the completion of the sale, the director now owns 8,500 shares in the company, valued at approximately $184,875. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Frederique Ph.D. Menzaghi sold 8,996 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $27.50, for a total value of $247,390.00. Following the sale, the insider now owns 119,886 shares of the company’s stock, valued at approximately $3,296,865. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 88,348 shares of company stock valued at $2,088,842. 5.80% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of CARA. Deutsche Bank AG lifted its holdings in shares of Cara Therapeutics by 141.9% during the 4th quarter. Deutsche Bank AG now owns 304,177 shares of the biopharmaceutical company’s stock valued at $3,953,000 after purchasing an additional 178,414 shares during the last quarter. First Manhattan Co. lifted its holdings in shares of Cara Therapeutics by 17.3% during the 1st quarter. First Manhattan Co. now owns 981,220 shares of the biopharmaceutical company’s stock valued at $19,251,000 after purchasing an additional 144,578 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cara Therapeutics during the 4th quarter valued at $1,578,000. BlackRock Inc. lifted its holdings in shares of Cara Therapeutics by 1.5% during the 4th quarter. BlackRock Inc. now owns 2,800,605 shares of the biopharmaceutical company’s stock valued at $36,407,000 after purchasing an additional 42,487 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of Cara Therapeutics by 109.5% during the 4th quarter. Two Sigma Advisers LP now owns 39,600 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 20,700 shares during the last quarter. Hedge funds and other institutional investors own 56.17% of the company’s stock.

Cara Therapeutics Company Profile (NASDAQ:CARA)

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

Featured Article: Why is the ROA ratio important?

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc. Buys 305020 Shares of Cara Therapeutics Inc (CARA)

Vanguard Group Inc. increased its position in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% during the third quarter, according to its most recent …

Cara Therapeutics logoVanguard Group Inc. increased its position in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,551,344 shares of the biopharmaceutical company’s stock after buying an additional 305,020 shares during the period. Vanguard Group Inc. owned 3.95% of Cara Therapeutics worth $37,155,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CARA. Pacer Advisors Inc. acquired a new position in Cara Therapeutics during the third quarter worth $138,000. Creative Planning acquired a new position in Cara Therapeutics during the third quarter worth $207,000. HAP Trading LLC raised its stake in Cara Therapeutics by 207.5% during the third quarter. HAP Trading LLC now owns 10,753 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 20,753 shares in the last quarter. Virtu Financial LLC acquired a new position in Cara Therapeutics during the third quarter worth $259,000. Finally, Raymond James & Associates acquired a new position in Cara Therapeutics during the second quarter worth $250,000. 62.16% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CARA traded up $0.08 during trading on Tuesday, hitting $17.13. 169,855 shares of the company’s stock traded hands, compared to its average volume of 624,717. Cara Therapeutics Inc has a 52 week low of $11.46 and a 52 week high of $24.30. The stock has a market capitalization of $669.89 million, a PE ratio of -9.21 and a beta of 2.87.

Several research analysts have issued reports on the company. Janney Montgomery Scott assumed coverage on Cara Therapeutics in a research note on Thursday, December 20th. They set a “buy” rating and a $13.36 price objective for the company. Zacks Investment Research lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 21st. HC Wainwright set a $30.00 target price on Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Bank of America assumed coverage on Cara Therapeutics in a research note on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price for the company. Finally, BidaskClub lowered Cara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $24.03.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $14.99, for a total transaction of $299,800.00. Following the transaction, the chief executive officer now owns 953,788 shares of the company’s stock, valued at approximately $14,297,282.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mani Mohindru sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $12.55, for a total value of $56,475.00. The disclosure for this sale can be found here. In the last three months, insiders sold 95,450 shares of company stock worth $1,266,845. 6.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Vanguard Group Inc. Buys 305,020 Shares of Cara Therapeutics Inc (CARA)” was first reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.fairfieldcurrent.com/news/2019/02/19/vanguard-group-inc-increases-stake-in-cara-therapeutics-inc-cara.html.

Cara Therapeutics Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

Featured Story: Day Trading

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc. Increases Stake in Cara Therapeutics Inc (CARA)

Vanguard Group Inc. lifted its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% in the 3rd quarter, according to its most recent filing with …

Cara Therapeutics logoVanguard Group Inc. lifted its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,551,344 shares of the biopharmaceutical company’s stock after purchasing an additional 305,020 shares during the period. Vanguard Group Inc. owned about 3.95% of Cara Therapeutics worth $37,155,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in CARA. Morgan Stanley lifted its holdings in Cara Therapeutics by 6.3% during the third quarter. Morgan Stanley now owns 81,338 shares of the biopharmaceutical company’s stock valued at $1,948,000 after purchasing an additional 4,840 shares in the last quarter. B. Riley Wealth Management Inc. purchased a new position in Cara Therapeutics during the third quarter valued at $882,000. TIAA CREF Investment Management LLC lifted its holdings in Cara Therapeutics by 19.2% during the third quarter. TIAA CREF Investment Management LLC now owns 70,240 shares of the biopharmaceutical company’s stock valued at $1,682,000 after purchasing an additional 11,312 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Cara Therapeutics by 15.4% during the third quarter. Teachers Advisors LLC now owns 63,265 shares of the biopharmaceutical company’s stock valued at $1,515,000 after purchasing an additional 8,461 shares in the last quarter. Finally, Nexthera Capital LP lifted its holdings in Cara Therapeutics by 69.2% during the third quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock valued at $17,658,000 after purchasing an additional 301,503 shares in the last quarter. 62.16% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CARA traded up $0.01 during midday trading on Tuesday, hitting $16.38. The company’s stock had a trading volume of 3,837 shares, compared to its average volume of 639,580. The company has a market cap of $660.08 million, a P/E ratio of -8.94 and a beta of 2.87. Cara Therapeutics Inc has a 12-month low of $11.46 and a 12-month high of $24.30.

Several equities analysts have issued reports on the stock. Cantor Fitzgerald set a $27.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 9th. BidaskClub downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 1st. Jefferies Financial Group assumed coverage on shares of Cara Therapeutics in a report on Wednesday, February 6th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Bank of America assumed coverage on shares of Cara Therapeutics in a report on Tuesday, January 15th. They set a “neutral” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.03.

In other news, CEO Derek T. Chalmers sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $14.99, for a total value of $299,800.00. Following the transaction, the chief executive officer now directly owns 953,788 shares of the company’s stock, valued at $14,297,282.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Terrillion sold 3,100 shares of the firm’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $12.51, for a total transaction of $38,781.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 111,492 shares of company stock worth $1,563,622. Insiders own 6.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/vanguard-group-inc-increases-stake-in-cara-therapeutics-inc-cara.html.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

Featured Story: What is Depreciation?

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Horrell Capital Management, Inc. Buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks …

Little Rock, AR, based Investment company Horrell Capital Management, Inc. buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks Inc, iKang Healthcare Group Inc, Nokia Oyj, Ribbon Communications Inc, iShares U.S. Preferred Stock ETF, Cara Therapeutics Inc, JD.com Inc, iShares Russell …

Little Rock, AR, based Investment company Horrell Capital Management, Inc. buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks Inc, iKang Healthcare Group Inc, Nokia Oyj, Ribbon Communications Inc, iShares U.S. Preferred Stock ETF, Cara Therapeutics Inc, JD.com Inc, iShares Russell 2000, sells Team Inc, LM Ericsson Telephone Co, Deltic Timber Corp, Heidrick & Struggles International Inc, Syntel Inc during the 3-months ended 2018-03-31, according to the most recent filings of the investment company, Horrell Capital Management, Inc.. As of 2018-03-31, Horrell Capital Management, Inc. owns 159 stocks with a total value of $184 million. These are the details of the buys and sells.

For the details of Horrell Capital Management, Inc.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Horrell+Capital+Management%2C+Inc.

These are the top 5 holdings of Horrell Capital Management, Inc.

  1. Union Pacific Corp (UNP) – 84,736 shares, 6.21% of the total portfolio. Shares added by 2.67%
  2. Dassault Systemes SE (DASTY) – 58,810 shares, 4.35% of the total portfolio. Shares added by 2.67%
  3. FedEx Corp (FDX) – 29,423 shares, 3.85% of the total portfolio. Shares added by 2.67%
  4. Bear State Financial Inc (BSF) – 668,868 shares, 3.74% of the total portfolio. Shares reduced by 21.85%
  5. Convergys Corp (CVG) – 300,000 shares, 3.7% of the total portfolio.

New Purchase: NetScout Systems Inc (NTCT)

Horrell Capital Management, Inc. initiated holding in NetScout Systems Inc. The purchase prices were between $25.5 and $31.35, with an estimated average price of $27.19. The stock is now traded at around $27.35. The impact to a portfolio due to this purchase was 2.43%. The holding were 169,000 shares as of 2018-03-31.

New Purchase: MicroStrategy Inc (MSTR)

Horrell Capital Management, Inc. initiated holding in MicroStrategy Inc. The purchase prices were between $123.87 and $140.98, with an estimated average price of $134.57. The stock is now traded at around $128.73. The impact to a portfolio due to this purchase was 2.39%. The holding were 34,009 shares as of 2018-03-31.

New Purchase: iKang Healthcare Group Inc (KANG)

Horrell Capital Management, Inc. initiated holding in iKang Healthcare Group Inc. The purchase prices were between $15.64 and $20, with an estimated average price of $16.81. The stock is now traded at around $20.03. The impact to a portfolio due to this purchase was 0.87%. The holding were 80,000 shares as of 2018-03-31.

New Purchase: iShares U.S. Preferred Stock ETF (PFF)

Horrell Capital Management, Inc. initiated holding in iShares U.S. Preferred Stock ETF. The purchase prices were between $36.79 and $38.19, with an estimated average price of $37.53. The stock is now traded at around $37.31. The impact to a portfolio due to this purchase was 0.01%. The holding were 500 shares as of 2018-03-31.

New Purchase: iShares Russell 2000 (IWM)

Horrell Capital Management, Inc. initiated holding in iShares Russell 2000. The purchase prices were between $145.44 and $159.96, with an estimated average price of $154.44. The stock is now traded at around $153.91. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 50 shares as of 2018-03-31.

New Purchase: Shopify Inc (SHOP)

Horrell Capital Management, Inc. initiated holding in Shopify Inc. The purchase prices were between $105.49 and $153.11, with an estimated average price of $129.43. The stock is now traded at around $122.05. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 50 shares as of 2018-03-31.

Added: Juniper Networks Inc (JNPR)

Horrell Capital Management, Inc. added to a holding in Juniper Networks Inc by 63.64%. The purchase prices were between $24.05 and $28.89, with an estimated average price of $26.58. The stock is now traded at around $24.78. The impact to a portfolio due to this purchase was 0.93%. The holding were 180,000 shares as of 2018-03-31.

Added: Nokia Oyj (NOK)

Horrell Capital Management, Inc. added to a holding in Nokia Oyj by 55.56%. The purchase prices were between $4.76 and $5.93, with an estimated average price of $5.39. The stock is now traded at around $5.61. The impact to a portfolio due to this purchase was 0.75%. The holding were 700,000 shares as of 2018-03-31.

Added: Ribbon Communications Inc (RBBN)

Horrell Capital Management, Inc. added to a holding in Ribbon Communications Inc by 61.75%. The purchase prices were between $5.08 and $7.83, with an estimated average price of $6.47. The stock is now traded at around $5.30. The impact to a portfolio due to this purchase was 0.54%. The holding were 510,800 shares as of 2018-03-31.

Added: GW Pharmaceuticals PLC (GWPH)

Horrell Capital Management, Inc. added to a holding in GW Pharmaceuticals PLC by 66.67%. The purchase prices were between $110.14 and $139.71, with an estimated average price of $125.74. The stock is now traded at around $118.95. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 100 shares as of 2018-03-31.

Added: Cara Therapeutics Inc (CARA)

Horrell Capital Management, Inc. added to a holding in Cara Therapeutics Inc by 100.00%. The purchase prices were between $11.77 and $16.08, with an estimated average price of $13.47. The stock is now traded at around $12.41. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 400 shares as of 2018-03-31.

Sold Out: Team Inc (TISI)

Horrell Capital Management, Inc. sold out a holding in Team Inc. The sale prices were between $13.2 and $18.75, with an estimated average price of $16.46.

Sold Out: LM Ericsson Telephone Co (ERIC)

Horrell Capital Management, Inc. sold out a holding in LM Ericsson Telephone Co. The sale prices were between $6.2 and $7.34, with an estimated average price of $6.73.

Sold Out: Deltic Timber Corp (DEL)

Horrell Capital Management, Inc. sold out a holding in Deltic Timber Corp. The sale prices were between $88.07 and $100.17, with an estimated average price of $93.41.

Sold Out: Heidrick & Struggles International Inc (HSII)

Horrell Capital Management, Inc. sold out a holding in Heidrick & Struggles International Inc. The sale prices were between $24.1 and $32.45, with an estimated average price of $27.31.

Sold Out: YuMe Inc (YUME)

Horrell Capital Management, Inc. sold out a holding in YuMe Inc. The sale prices were between $3.66 and $4.8, with an estimated average price of $4.36.

Sold Out: Cray Inc (CRAY)

Horrell Capital Management, Inc. sold out a holding in Cray Inc. The sale prices were between $20.05 and $25.85, with an estimated average price of $23.18.

Reduced: Syntel Inc (SYNT)

Horrell Capital Management, Inc. reduced to a holding in Syntel Inc by 95%. The sale prices were between $21.2 and $27.44, with an estimated average price of $24.78. The stock is now traded at around $25.25. The impact to a portfolio due to this sale was -1.16%. Horrell Capital Management, Inc. still held 5,000 shares as of 2018-03-31.

Reduced: Bear State Financial Inc (BSF)

Horrell Capital Management, Inc. reduced to a holding in Bear State Financial Inc by 21.85%. The sale prices were between $10.22 and $10.32, with an estimated average price of $10.27. The stock is now traded at around $10.30. The impact to a portfolio due to this sale was -1.02%. Horrell Capital Management, Inc. still held 668,868 shares as of 2018-03-31.

Reduced: Marchex Inc (MCHX)

Horrell Capital Management, Inc. reduced to a holding in Marchex Inc by 58.56%. The sale prices were between $2.64 and $3.55, with an estimated average price of $3.23. The stock is now traded at around $2.67. The impact to a portfolio due to this sale was -0.4%. Horrell Capital Management, Inc. still held 166,117 shares as of 2018-03-31.

Reduced: Allot Communications Ltd (ALLT)

Horrell Capital Management, Inc. reduced to a holding in Allot Communications Ltd by 57.73%. The sale prices were between $4.85 and $5.74, with an estimated average price of $5.33. The stock is now traded at around $5.44. The impact to a portfolio due to this sale was -0.36%. Horrell Capital Management, Inc. still held 94,300 shares as of 2018-03-31.

Reduced: Campbell Soup Co (CPB)

Horrell Capital Management, Inc. reduced to a holding in Campbell Soup Co by 33.33%. The sale prices were between $42.02 and $48.11, with an estimated average price of $45.12. The stock is now traded at around $43.06. The impact to a portfolio due to this sale was -0.01%. Horrell Capital Management, Inc. still held 500 shares as of 2018-03-31.

Here is the complete portfolio of Horrell Capital Management, Inc.. Also check out:

1. Horrell Capital Management, Inc.’s Undervalued Stocks

2. Horrell Capital Management, Inc.’s Top Growth Companies, and

3. Horrell Capital Management, Inc.’s High Yield stocks

4. Stocks that Horrell Capital Management, Inc. keeps buying

Related Posts: